OS4.1 MEVITEM: A European, randomized, open-label, Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog (SHH) pathway

BACKGROUND: Vismodegib (V) suppresses sonic hedgehog (SHH) signaling. We postulated that vismodegib together with chemotherapy may be more efficient than chemotherapy alone in patients (pts) relapsing of a SHH-activated medulloblastoma (MB). MATERIAL AND METHODS: Adult pts with recurrent SHH-MB not...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Frappaz, D, Barritault, M, Montané, L, Laigle-Donadey, F, Chinot, O, Le Rhun, E, Bonneville-Levard, A, Meyronnet, D, Garin, G, Pérol, D
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Oral Presentations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795008/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.031
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires